Get the Stockscreener App
4.82
4.10%
0.19
Pre-market:
4.82
Maravai Lifesciences Holdings Inc stock is traded at $4.82, with a volume of 1.62M.
It is up +4.10% in the last 24 hours and down -42.28% over the past month.
Maravai LifeSciences Holdings Inc is a life sciences company. It provides products to enable the development of drug therapies, diagnostics, and novel vaccines and supports research on human diseases. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.
See More
Previous Close:
$4.63
Open:
$4.74
24h Volume:
1.62M
Relative Volume:
0.92
Market Cap:
$656.74M
Revenue:
$288.95M
Net Income/Loss:
$-119.03M
P/E Ratio:
8.4636
EPS:
0.5695
Net Cash Flow:
$60.67M
1W Performance:
-14.39%
1M Performance:
-42.28%
6M Performance:
-57.50%
1Y Performance:
-2.23%
1-Day Range:
$4.62
$5.055
1-Week Range:
$4.275
$5.57
52-Week Range:
$4.275
$11.55
Maravai Lifesciences Holdings Inc Stock (MRVI) Company Profile
Name
Maravai Lifesciences Holdings Inc
Sector
Industry
Phone
(858) 546-0004
Address
10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO
Compare MRVI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| MRVI | 4.82 | 656.74M | 288.95M | -119.03M | 60.67M | 0.5695 |
| VRTX | 451.23 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 743.35 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.82 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.79 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.14 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Maravai Lifesciences Holdings Inc Stock (MRVI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-08-23 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| May-23-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| May-09-23 | Downgrade | Goldman | Buy → Neutral |
| Jan-05-23 | Downgrade | UBS | Buy → Neutral |
| Dec-14-22 | Initiated | Deutsche Bank | Buy |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Nov-03-22 | Downgrade | BofA Securities | Buy → Neutral |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Dec-16-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Dec-15-20 | Initiated | BofA Securities | Buy |
| Dec-15-20 | Initiated | Credit Suisse | Outperform |
| Dec-15-20 | Initiated | Goldman | Buy |
| Dec-15-20 | Initiated | Jefferies | Buy |
| Dec-15-20 | Initiated | Robert W. Baird | Outperform |
| Dec-15-20 | Initiated | Stifel | Buy |
| Dec-15-20 | Initiated | William Blair | Outperform |
| Dec-14-20 | Initiated | UBS | Buy |
View All
Maravai Lifesciences Holdings Inc Stock (MRVI) Latest News
Wolfe Research Initiates Coverage of Maravai LifeSciences Holdings (MRVI) with Peer Perform Recommendation - MSN
What Do Analysts Think About Maravai LifeSciences Holdings Inc’s (NASDAQ:MRVI) Future? - Stocks Register
Royce & Associates LP Increases Stock Holdings in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) - MarketBeat
Maravai LifeSciences (NASDAQ:MRVI) Trading Down 7.5%Here's What Happened - MarketBeat
(MRVI) Trading Report - Stock Traders Daily
Maravai Lifesciences stock hits 52-week low at $4.68 - Investing.com
Steven Cohen's Strategic Acquisition in Maravai LifeSciences - GuruFocus.com
Maravai LifeSciences shares initiated with Peerperform on positive aspects - Investing.com India
Maravai lifesci director John DeFord acquires $100,625 in stock - Investing.com
Insider Buying: Director John Deford Acquires Shares of Maravai LifeSciences Holdings Inc (MRVI) - GuruFocus.com
Maravai LifeSciences shares initiated with Peerperform on positive aspects By Investing.com - Investing.com Canada
Maravai LifeSciences (NASDAQ:MRVI) Now Covered by Wolfe Research - MarketBeat
Maravai LifeSciences Target of Unusually Large Options Trading (NASDAQ:MRVI) - MarketBeat
12 West Capital Management LP's Strategic Acquisition in Maravai LifeSciences Holdings Inc - GuruFocus.com
Maravai LifeSciences (NASDAQ:MRVI) Shares Gap Up Following Insider Buying Activity - MarketBeat
Maravai LifeSciences Announces November 2024 Investor Conference Schedule - GlobeNewswire
Earnings call: Maravai LifeSciences reports mixed Q3 results, eyes growth - Investing.com India
Maravai LifeSciences (NASDAQ:MRVI) Price Target Cut to $13.00 by Analysts at Royal Bank of Canada - Defense World
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Q3 2024 Earnings Call Transcript - Insider Monkey
Slammed 37% Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Screens Well Here But There Might Be A Catch - Simply Wall St
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Just Reported Earnings, And Analysts Cut Their Target Price - Yahoo Finance
Maravai LifeSciences (NASDAQ:MRVI) Shares Gap Down on Analyst Downgrade - Defense World
Maravai Lifesciences price target lowered to $9 from $10 at Baird - Yahoo Finance
Health Care Up on Another Round of Mixed Earnings -- Health Care Roundup - Marketscreener.com
Royal Bank of Canada Has Lowered Expectations for Maravai LifeSciences (NASDAQ:MRVI) Stock Price - MarketBeat
Maravai LifeSciences stock plunges 39% amid lowered revenue forecast - MSN
Maravai LifeSciences stock plunges 39% amid lowered revenue forecast (NASDAQ:MRVI) - Seeking Alpha
U.S. Stock market: Evolent Health(-43.35%), Maravai LifeSciences(-38.65%), and Chanson International(-38.04%) in midday trading - Business Upturn
Maravai LifeSciences (NASDAQ:MRVI) Shares Gap Down Following Analyst Downgrade - MarketBeat
U.S. Stock market: Evolent Health (-41.07%), Maravai LifeSciences(-34.44%), Revance Therapeutics(-32.01%) as top losers during early trading - Business Upturn
Maravai LifeSciences (NASDAQ:MRVI) Given New $9.00 Price Target at Robert W. Baird - MarketBeat
Maravai LifeSciences' (MRVI) Market Perform Rating Reaffirmed at William Blair - MarketBeat
Decoding 5 Analyst Evaluations For Maravai LifeSciences - Benzinga
Maravai LifeSciences (MRVI) Q3 2024 Earnings Call Transcript - AOL
Maravai LifeSciences Holdings Inc (MRVI) Q3 2024 Earnings Call Highlights: Navigating ... By GuruFocus - Investing.com Canada
Maravai LifeSciences Holdings Inc (MRVI) Q3 2024 Earnings Call Highlights: Navigating ... - Yahoo Finance
Maravai LifeSciences Plans to Acquire DNA and RNA Business of Officinae Bio, Advancing Support for Innovative Nucleic Acid Research - BioSpace
Maravai LifeSciences Reports Q3 Earnings and Strategic Acquisition - TipRanks
Maravai LifeSciences stock plunges on weak Q3 results, lowered guidance By Investing.com - Investing.com South Africa
Maravai LifeSciences stock plunges on weak Q3 results, lowered guidance - Investing.com
Maravai Lifesciences earnings missed by $0.01, revenue fell short of estimates - Investing.com UK
Maravai to acquire Officinae Bio's DNA, RNA business By Investing.com - Investing.com South Africa
Maravai LifeSciences Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Maravai LifeSciences Reports Third Quarter 2024 Financial Results - GlobeNewswire
Maravai LifeSciences Holdings Inc (MRVI) Recovers 77.65% From Low: Are We There Yet? - Stocks Register
Maravai LifeSciences Holdings (STU:MAR) Growth Rank : 8 (As of Nov. 05, 2024) - GuruFocus.com
(MRVI) Investment Analysis and Advice - Stock Traders Daily
Maravai LifeSciences Holdings (STU:MAR) GF Value Rank : 9 (As of Nov. 05, 2024) - GuruFocus.com
MRVI Stock Surges Amid Biotechnology Sector Fluctuations - GuruFocus.com
Cannon Global Investment Management LLC Makes New $590,000 Investment in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) - MarketBeat
Roubaix Capital LLC Trims Holdings in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) - MarketBeat
Maravai Lifesciences Holdings Inc Stock (MRVI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.69%
6.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):